For information on HAE and the COVID-19 vaccine please click the COVID-19 vaccine menu item to the left.
We’ve Launched Our 2020 National Report Card

HAE Canada sent all our members links to the 2020 National Report Card survey. This important survey will allow HAE Canada to understand patient product use so we may continue to advocate for improved access to new, and current, safe and effective HAE treatments.
This information will aid in our current Advocacy campaign to list HAEGARDA through CBS and to expedite access to TAKHZYRO through the many Provincial and Federal Jurisdictions. We also require this data to show a need for Canadian research for HAE with normal C1.
Only HAE Canada members can fill out the survey. If you are a member and you did not receive the survey, please email office@haecanada.org to request your link. If you are or care for a HAE patient, please consider joining HAE Canada and fill out the survey.
Completing this survey will also give members a chance to win a travel grant to attend the next HAEi Global Conference.
Latest News
Ontario is the latest province provide access to Takhzyro!
We are excited to share that Ontario is the latest province to provide access to lanadelumab (TAKHZYRO) to HAE patients. When the Ontario Ministry of Health issued its
New Brunswick has added TAKHZYRO to their Provincial Drug Plan!
Another province has added TAKHZYRO to their provincial formulary! As of January 27th, 2021, Type I & II HAE patients in New Brunswick have access to lanadelumab (Takhzyro)
Takeda’s Patient Resource myHAEcheckup.ca is now available!
You deserve to live your best life. However, living with HAE can be difficult, even between attacks. Takeda Inc. is introducing a new, comprehensive resource designed to help
A New CSL Behring Patient Support Program
We wanted to let our members know that starting February 1st, 2021, CSL Behring patient support programs (Hizentra™ CARE Program, and Berinert® Assistance Program) will be streamlined into
Have no fear, the COVID vaccine is safe
Recently, HAE International's President and CEO, Tony Castaldo interviewed Prof. Dr. Marcus Maurer to discuss HAE patients and the COVID vaccine. We encourage everyone to please watch this
TAKHZYRO Now Available in Alberta
We are thrilled to share that as of December 1st, 2020, Type I & II HAE patients in Alberta have access to lanadelumab (Takhzyro) through the province's Drug
TAKHZYRO: One Step Closer
Amazing news! Canadian HAE patients are one step closer to gaining equitable access to the new treatment, TAKHZYRO! After months of negotiations, Takeda Canada announced it has completed
Terrific News for HAE Patients in Quebec
We have some exciting news to share! We are pleased to let everyone know the Institut national d’excellence en santé et en services sociaux (INESSS) has reevaluated lanadelumab
Canada Won the 2020 HAE Global Walk
Thank you to the amazing HAE Community here in Canada - Canada won the Virtual 2020 HAE Global Walk; an annual event organized by the HAE International team.
Great News!
HAEGARDA and TAKHZYRO are now available in Canada. Please talk to your HAE specialist about access. Thank you Canadian Blood Services (CBS) for a very collaborative, informative and
HAE Day 2020
For HAE Day 2020, HAE Canada wants to celebrate! To honour the day we have two BIG announcements: 1) Our website received a facelift! We hope our
Virtual HAE Global Walk
It’s time, once again, for HAE Canada to please ask you to take out your walking shoes and participate in the virtual HAE Global Walk arranged by HAE
HAE Canada’s message on COVID-19
HAE Canada continues to remain focused on the health and well-being of patients with hereditary angioedema, and other related angioedema, in Canada. We would like to share what
HAEGARDA is available in Quebec
We are thrilled to let the HAE community know that HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) is now available to HAE patients in Quebec. HAEGARDA is a subcutaneous
Support Family Testing
Give valuable insights in HAE science
Hereditary Angioedema (HAE) is a hereditary disorder. It is therefore very important to have other family members tested. To help you in this process HAE International has developed two documents for patients. You can download the documents below:
